A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO) - Concepedia

Concepedia

Publication | Open Access

A randomized phase II study of paclitaxel alone versus paclitaxel plus sorafenib in second- and third-line treatment of patients with HER2-negative metastatic breast cancer (PASO)

DOI Full Paper Access

26

Citations

32

References

2017

Year

Thomas Decker, Friedrich Overkamp, Siegfried Rösel, Arnd Nusch, Thomas Göhler, Martin Indorf, Jörg Sahlmann, Tanja Trarbach

Abstract

The study was registered at EudraCT (No 2009-018025-73) and retrospectively registered at Clinical trials.gov on March 17, 2011 ( NCT01320111 ).

References

	Year	Citations

Page 1